Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Clin Nutr ; 40(1): 181-189, 2021 01.
Article in English | MEDLINE | ID: mdl-32460959

ABSTRACT

BACKGROUND & AIMS: Anorexia Nervosa is a severe disease depending on both biological, psychological and environmental factors. The gut microbiota has recently been proposed as one of the biological factors potentially involved in the onset or maintenance of Anorexia Nervosa. To unravel the potential role of the gut microbiota in this disease, we characterized the dysbiosis occurring in a mouse model of Anorexia and correlated bacteria level changes with different physiological parameters such as body weight, food intake or levels of hypothalamic neuropeptides. METHODS: We used the Activity-Based Anorexia (ABA) mouse model, which combines food restriction and physical activity, and which mimics core features of Anorexia Nervosa. We characterized the gut microbiota alteration in ABA mice by combining 16S rRNA gene sequencing and quantitative PCR analyses of targeted genera or species. RESULTS: We identified 68 amplicon sequence variants (ASVs) with decreased levels and 8 ASVs with increased levels in the cecal content of ABA mice compared to control mice. We observed in particular in ABA mice increases in the abundance of Clostridium cocleatum and several Lactobacillus species and a decrease in the abundance of Burkholderiales compared to control mice. Interestingly, we show that most of the observed gut microbiota alterations are due to food restriction and are not affected by physical activity. In addition, we identified several bacterial groups that correlate with mice body weight, food intake, lean and fat masses as well as with hypothalamic mRNA levels of NPY (Neuropeptide Y) and POMC (Pro-opiomelanocortin). CONCLUSIONS: Our study provides a comprehensive characterization of the gut microbiota dysbiosis occurring in the Activity-Based Anorexia mouse model. These data constitute a valuable resource to further decipher the role of the gut microbiota in the different facets of anorexia pathophysiology, such as functional gastrointestinal disorders, appetite regulation and mood disorders.


Subject(s)
Anorexia Nervosa/microbiology , Dysbiosis/microbiology , Gastrointestinal Microbiome/physiology , Animals , Body Weight , Disease Models, Animal , Eating , Hypothalamus/metabolism , Mice , Neuropeptides/metabolism , RNA, Messenger/metabolism , RNA, Ribosomal, 16S/analysis , Real-Time Polymerase Chain Reaction
2.
Sci Rep ; 8(1): 7233, 2018 05 08.
Article in English | MEDLINE | ID: mdl-29740148

ABSTRACT

Restrictive anorexia nervosa is associated with reduced eating and severe body weight loss leading to a cachectic state. Hypothalamus plays a major role in the regulation of food intake and energy homeostasis. In the present study, alterations of hypothalamic proteome and particularly of proteins involved in energy and mitochondrial metabolism have been observed in female activity-based anorexia (ABA) mice that exhibited a reduced food intake and a severe weight loss. In the hypothalamus, mitochondrial dynamic was also modified during ABA with an increase of fission without modification of fusion. In addition, increased dynamin-1, and LC3II/LC3I ratio signed an activation of autophagy while protein synthesis was increased. In conclusion, proteomic analysis revealed an adaptive hypothalamic protein response in ABA female mice with both altered mitochondrial response and activated autophagy.


Subject(s)
Anorexia Nervosa/genetics , Dynamin I/genetics , Hypothalamus/metabolism , Microtubule-Associated Proteins/genetics , Mitochondrial Dynamics/genetics , Proteome/genetics , Aconitate Hydratase/genetics , Aconitate Hydratase/metabolism , Animals , Anorexia , Anorexia Nervosa/metabolism , Anorexia Nervosa/physiopathology , Autophagy/genetics , Disease Models, Animal , Dynamin I/metabolism , Eating/genetics , Female , Gene Expression Profiling , Gene Expression Regulation , Hypothalamus/physiopathology , Mice , Mice, Inbred C57BL , Microtubule-Associated Proteins/metabolism , Physical Conditioning, Animal , Protein Biosynthesis , Protein Isoforms/genetics , Protein Isoforms/metabolism , Proteome/metabolism , Receptors, Enterotoxin/genetics , Receptors, Enterotoxin/metabolism , Signal Transduction , Weight Loss/genetics
3.
Eur Neuropsychopharmacol ; 26(6): 948-58, 2016 06.
Article in English | MEDLINE | ID: mdl-27052473

ABSTRACT

Stimulation of feeding is necessary for treatment of pathological conditions of chronic malnutrition due to anorexia. Ghrelin, a hunger hormone, is one of the candidate for pharmacological treatments of anorexia, but because of its instability in plasma has limited efficacy. We previously showed that plasmatic IgG protect ghrelin from degradation and that IgG from obese subjects and mice may increase ghrelin׳s orexigenic effect. In this study we tested if ghrelin alone or combined with IgG may improve feeding in chronically food-restricted mice with or without physical activity-based anorexia (ABA) induced by free access to a running wheel. Mice received a single daily intraperitoneal injection of ghrelin (1nM) together or not with total IgG (1nM) from obese ob/ob or lean mice before access to food during 8 days of 3h/day feeding time. We found that both ghrelin and ghrelin combined with IgG from obese, but not lean mice, prevented ABA, however, they were not able to diminish body weight loss. Physical activity was lower during the feeding period and was increased shortly after feeding in mice receiving ghrelin together with IgG from obese mice. In food-restricted mice without ABA, ghrelin treatments did not have significant effects on food intake. Thus, this study supports pharmacological use of ghrelin or ghrelin combined with IgG from obese animals for treatment of anorexia accompanied by elevated physical activity. The utility of combining ghrelin with protective IgG should be further determined in animal models of anorexia with unrestricted access to food.


Subject(s)
Anorexia/prevention & control , Ghrelin/therapeutic use , Motor Activity , Animals , Anorexia/psychology , Antibodies, Blocking/pharmacology , Body Weight/drug effects , Caloric Restriction , Eating/drug effects , Ghrelin/antagonists & inhibitors , Ghrelin/blood , Hypothalamus/drug effects , Hypothalamus/metabolism , Immunoglobulin G/immunology , Injections, Intraperitoneal , Male , Mice , Mice, Inbred C57BL , Obesity/immunology
4.
Cell Metab ; 23(2): 324-34, 2016 Feb 09.
Article in English | MEDLINE | ID: mdl-26621107

ABSTRACT

The composition of gut microbiota has been associated with host metabolic phenotypes, but it is not known if gut bacteria may influence host appetite. Here we show that regular nutrient provision stabilizes exponential growth of E. coli, with the stationary phase occurring 20 min after nutrient supply accompanied by bacterial proteome changes, suggesting involvement of bacterial proteins in host satiety. Indeed, intestinal infusions of E. coli stationary phase proteins increased plasma PYY and their intraperitoneal injections suppressed acutely food intake and activated c-Fos in hypothalamic POMC neurons, while their repeated administrations reduced meal size. ClpB, a bacterial protein mimetic of α-MSH, was upregulated in the E. coli stationary phase, was detected in plasma proportional to ClpB DNA in feces, and stimulated firing rate of hypothalamic POMC neurons. Thus, these data show that bacterial proteins produced after nutrient-induced E. coli growth may signal meal termination. Furthermore, continuous exposure to E. coli proteins may influence long-term meal pattern.


Subject(s)
Escherichia coli Proteins/metabolism , Escherichia coli/growth & development , Gastrointestinal Tract/microbiology , Satiety Response , Adenosine Triphosphate/biosynthesis , Amygdala/metabolism , Animals , Electrophysiological Phenomena , Endopeptidase Clp , Escherichia coli/metabolism , Feeding Behavior , Female , Glucagon-Like Peptide 1/metabolism , Heat-Shock Proteins/metabolism , Hypothalamus/metabolism , Male , Mice , Mice, Inbred C57BL , Neurons/metabolism , Peptide YY/metabolism , Pro-Opiomelanocortin/metabolism , Proteomics , Proto-Oncogene Proteins c-fos/metabolism , Rats, Sprague-Dawley , Rats, Wistar
5.
Neuropeptides ; 51: 17-23, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25963530

ABSTRACT

Plasma levels of ghrelin, an orexigenic peptide, are increased during conditions of chronic starvation, such as in patients with anorexia nervosa. However, it is not known whether such increase can be related to the number of preproghrelin mRNA-expressing cells in the stomach, and if chronic starvation may activate a tentative central ghrelin production. In this work, in situ hybridization technique was used to analyze the presence and number of preproghrelin mRNA-expressing cells in the stomach and the hypothalamus of mice with activity-based anorexia (ABA) induced by the combination of running wheel activity with progressive, during 10 days, feeding-time restriction (FTR) and compared with sedentary FTR, ABA pair-fed (PF) and ad libitum-fed control mice. All food-restricted mice lost more than 20% of body weight. Body weight loss was similar in ABA and PF mice, but it was more pronounced than in FTR mice. Food intake was also lower in ABA than in FTR mice. Preproghrelin mRNA-expressing cells in the stomach were increased proportionally to the body weight loss in all food-restricted groups with the highest number in ABA mice. No preproghrelin mRNA-producing cells were detectable in the hypothalamus of either control or food-restricted mice. Thus, the increased number of gastric preproghrelin mRNA-producing cells during chronic starvation proportionally to the body weight loss and reduced food intake may underlie increased plasma ghrelin. Hyperactivity-induced anorexia appears to further increase the number of preproghrelin mRNA-producing cells in the stomach. No evidence was found for ghrelin expression in the hypothalamus, not even in any of the present experimental models.


Subject(s)
Anorexia/metabolism , Eating/physiology , Gastric Mucosa/metabolism , Ghrelin/metabolism , Motor Activity/physiology , RNA, Messenger/metabolism , Animals , Anorexia/genetics , Body Weight/physiology , Ghrelin/genetics , Hypothalamus/metabolism , Male , Mice , RNA, Messenger/genetics
6.
Nutrition ; 31(3): 498-507, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25701341

ABSTRACT

OBJECTIVES: The biological background of sex-related differences in the development of eating disorders (EDs) is unknown. Recent data showed that gut bacteria Escherichia coli induce autoantibodies against anorexigenic α-melanocyte-stimulating hormone (α-MSH) associated with psychopathology in ED. The aim of this study was to compare the effects of E. coli on feeding and autoantibodies against α-MSH and adrenocorticotropic hormone (ACTH), between female and male rats. METHODS: Commensal E. coli K12 were given in a culture medium daily to adult Wistar rats by intragastric gavage over a 3-wk period; control rats received culture medium only. RESULTS: Before gavage, E. coli K12 DNA was detected in feces of female but not male rats. E. coli provision was accompanied by an increase in body weight gain in females, but a decrease in body weight gain and food intake in males. Independent of E. coli treatment, plasma levels of anti-α-MSH and ACTH immunoglobulin (Ig)G were higher in female than male rats. Females responded to E. coli by increasing α-MSH IgG levels and affinity, but males by increasing α-MSH IgM levels. Affinity of IgG for ACTH was increased in both E. coli-treated females and males, although with different kinetics. IgG from females stimulated more efficiently α-MSH-induced cyclic adenosine monophosphate production by melanocortin 4 receptor-expressing cells compared with IgG from males. DISCUSSION: Sex-related response to how E. coli affects feeding and anti-melanocortin hormone antibody production may depend on the presence of these bacteria in the gut before E. coli supplementation. These data suggest that sex-related presence of certain gut bacteria may represent a risk factor for ED development.


Subject(s)
Autoantibodies/blood , Colon/microbiology , Eating/immunology , Escherichia coli , Feeding and Eating Disorders/microbiology , Gastrointestinal Microbiome/immunology , Melanocortins/immunology , Adenosine Monophosphate/metabolism , Adrenocorticotropic Hormone/immunology , Animals , Dietary Supplements , Feces/microbiology , Feeding and Eating Disorders/immunology , Female , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Probiotics , Rats, Wistar , Receptor, Melanocortin, Type 4/metabolism , Sex Factors , Weight Gain , alpha-MSH/immunology
7.
Peptides ; 55: 145-50, 2014 May.
Article in English | MEDLINE | ID: mdl-24632335

ABSTRACT

As part of our continuing studies on the structure-activity relationships of cyclic pentapeptides based on the structure of endomorphin-2, we report here the synthesis and biological activities of a new series of analogs incorporating 2', 3' or 4'-methylphenylalanine (MePhe) residues into positions 3 or 4 of the parent cyclopeptide, Dmt-c[d-Lys-Phe-Phe-Asp]NH2 (Dmt=2',6'-dimethyltyrosine). Analogs with MePhe in position 4 showed a row of magnitude increased µ-opioid receptor (MOP receptor) affinity as compared with a parent compound. The in vitro potencies of the new analogs were determined in calcium mobilization assay performed in Chinese Hamster Ovary (CHO) cells expressing human recombinant opioid receptors and chimeric G proteins. All analogs were strong µ/κ (MOP/KOP) receptor agonists and weak δ (DOP) receptor agonists. In the in vivo hot-plate test in mice, the MePhe(4)-modified peptides showed remarkable antinociceptive activity after intracerebroventricular (i.c.v.) administration which was most likely due to the concomitant activation of more than one opioid receptor type.


Subject(s)
Analgesics, Opioid/administration & dosage , Oligopeptides/administration & dosage , Receptors, Opioid, delta/agonists , Analgesics, Opioid/chemistry , Animals , CHO Cells , Cricetinae , Cricetulus , Drug Evaluation, Preclinical , Humans , Inhibitory Concentration 50 , Injections, Intraventricular , Male , Mice , Oligopeptides/chemistry , Phenylalanine/analogs & derivatives , Phenylalanine/chemistry , Protein Binding , Rats, Wistar , Receptors, Opioid, delta/metabolism , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/metabolism , Structure-Activity Relationship
8.
J Ethnopharmacol ; 145(1): 59-66, 2013 Jan 09.
Article in English | MEDLINE | ID: mdl-23107823

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Passiflora alata is a Southern American species that constitutes many traditional remedies as well as phytomedicines used for sedative and anxiolytic purposes in Brazil. However studies on repeated treatment effects are scarce. AIM OF THE STUDY: To evaluate behavioral, physiological and biochemical effects of the repeated treatment with an aqueous spray-dried extract of Passiflora alata leaves containing 2.5% (w/v) of flavonoids (PA) in mice. MATERIAL AND METHODS: Male adult CF1 mice were treated (p.o.) for 14 days with PA (2.5; 25 or 250 mg/kg). The feeding behavior was evaluated at the beginning (1h after the first administration) and at the end of the treatment (15th day). The body weight gain and food consumption were monitored along the days. On day 15 mice were evaluated on plus maze, spontaneous locomotor activity, catalepsy and barbiturate sleeping time tests. Serum glucose, lipids, ALT and AST enzymes were determined. Liver, kidney, perirenal fat, epididymal and peritoneal fat were analyzed. RESULTS: The repeated treatment with the highest dose tested (250 mg/kg) did not alter the mice behavior on open field, elevated plus maze, catalepsy and barbiturate sleeping time tests. Repeated administration of PA 250 decreased mice feeding behavior and weight gain. PA 25 and PA 250 reduced mice relative liver weight and caused mild hepatic hydropic degeneration as well as a decrease in alanine aminotransferase (ALT) serum level. CONCLUSIONS: These results indicate that Passiflora alata does not present central cumulative effects and point to the needs of further studies searching for its hepatotoxicity as well as potential anorexigenic.


Subject(s)
Behavior, Animal/drug effects , Body Weight/drug effects , Passiflora/chemistry , Plant Extracts/pharmacology , Alanine Transaminase/blood , Alanine Transaminase/drug effects , Animals , Animals, Outbred Strains , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/drug effects , Blood Glucose/drug effects , Dose-Response Relationship, Drug , Eating/drug effects , Male , Mice , Organ Size/drug effects , Plant Extracts/chemistry , Plant Leaves/chemistry
9.
Psychoneuroendocrinology ; 37(9): 1457-67, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22365482

ABSTRACT

Depression and eating disorders are frequently associated, but the molecular pathways responsible for co-occurrence of altered mood, appetite and body weight are not yet fully understood. Neuropeptide Y (NPY) has potent antidepressant and orexigenic properties and low central NPY levels have been reported in major depression. In the present study, we hypothesized that in patients with major depression alteration of mood, appetite and body weight may be related to NPY-reactive autoantibodies (autoAbs). To test this hypothesis, we compared plasma levels and affinities of NPY-reactive autoAbs between patients with major depression and healthy controls. Then, to evaluate if changes of NPY autoAb properties can be causally related to altered mood and appetite, we developed central and peripheral passive transfer models of human autoAbs in mice and studied depressive-like behavior in forced-swim test and food intake. We found that plasma levels of NPY IgG autoAbs were lower in patients with moderate but not with mild depression correlating negatively with the Montgomery-Åsberg Depression Rating Scale scores and with immobility time of the forced-swim test in mice after peripheral injection of autoAbs. No significant differences in NPY IgG autoAb affinities between patients with depression and controls were found, but higher affinity of IgG autoAbs for NPY was associated with lower body mass index and prevented NPY-induced orexigenic response in mice after their central injection. These data suggest that changes of plasma levels of anti-NPY autoAbs are relevant to altered mood, while changes of their affinity may participate in altered appetite and body weight in patients with depressive disorder.


Subject(s)
Affect/physiology , Appetite/physiology , Autoantibodies/blood , Depressive Disorder, Major/immunology , Neuropeptide Y/immunology , Adult , Amygdala/drug effects , Amygdala/metabolism , Animals , Autoantibodies/pharmacology , Depressive Disorder, Major/blood , Depressive Disorder, Major/psychology , Eating/drug effects , Eating/immunology , Humans , Hypothalamus/drug effects , Hypothalamus/metabolism , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin G/pharmacology , Male , Mice , Middle Aged , Neuropeptide Y/metabolism , Neuropeptide Y/pharmacology , Pro-Opiomelanocortin/genetics , Pro-Opiomelanocortin/metabolism , Swimming
10.
Behav Brain Res ; 228(1): 66-73, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22155486

ABSTRACT

In this study we have demonstrated that cyclohexane extract of Hypericum polyanthemum (POL) and its main phloroglucinol derivative uliginosin B (ULI) present antidepressant-like activity in rodent forced swimming test (FST). The involvement of monoaminergic neurotransmission on the antidepressant-like activity of ULI was evaluated in vivo and in vitro. POL 90 mg/kg (p.o.) and ULI 10 mg/kg (p.o.) reduced the immobility time in the mice FST without altering locomotion activity in the open-field test. The combination of sub-effective doses of POL (45 mg/kg, p.o.) and ULI (5 mg/kg, p.o.) with sub-effective doses of imipramine (10 mg/kg, p.o.), bupropion (3 mg/kg, p.o.) and fluoxetine (15 mg/kg, p.o.) induced a significant reduction on immobility time in FST. The pretreatment with SCH 23390 (15 µg/kg, s.c., dopamine D1 receptor antagonist), sulpiride (50 mg/kg, i.p., dopamine D2 receptor antagonist), prazosin (1mg/kg, i.p., α1-adrenoceptor antagonist), yohimbine (1mg/kg, i.p., α2-adrenoceptor antagonist) and pCPA (100 mg/kg/day, i.p., p-chlorophenilalanine methyl ester, inhibitor of serotonin synthesis, for four consecutive days) before ULI administration (10 mg/kg, p.o.) significantly prevented the anti-immobility effect in FST. ULI was able to inhibit synaptosomal uptake of dopamine (IC50 = 90 ± 38 nM), serotonin (IC50 = 252 ± 13 nM) and noradrenaline (280 ± 48 nM), but it did not bind to any of the monoamine transporters. These data firstly demonstrated the antidepressant-like effect of POL and ULI, which depends on the activation of the monoaminergic neurotransmission in a different manner from the most antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Hypericum/chemistry , Phloroglucinol/analogs & derivatives , Animals , Antidepressive Agents/isolation & purification , Benzazepines/pharmacology , Biogenic Monoamines/metabolism , Bupropion/pharmacology , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/psychology , Enzyme Inhibitors/pharmacology , Fenclonine/pharmacology , Fluoxetine/pharmacology , Imipramine/pharmacology , Immobility Response, Tonic/drug effects , Locomotion/drug effects , Male , Mice , Mice, Inbred Strains , Phloroglucinol/antagonists & inhibitors , Phloroglucinol/isolation & purification , Phloroglucinol/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Prazosin/pharmacology , Rats , Rats, Wistar , Receptors, Catecholamine/antagonists & inhibitors , Sulpiride , Vesicular Monoamine Transport Proteins/metabolism , Yohimbine/pharmacology
11.
Psychoneuroendocrinology ; 34(1): 140-9, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18842346

ABSTRACT

alpha-Melanocyte-stimulating hormone (alpha-MSH) is a stress-related neuropeptide involved in the regulation of motivated behavior, appetite and emotion including stimulation of satiety and anxiety. Although autoantibodies (autoAbs) reactive with alpha-MSH have been identified in human subjects and in rats, it remained unknown if these autoAbs are involved in the regulation of feeding and anxiety and if their production is related to stress. Here we show that repeated exposure of rats to anxiolytic mild stress by handling increases the levels and affinity of alpha-MSH reactive IgG autoAbs and that these changes are associated with adaptive feeding and anxiety responses during exposure of rats to a strong stress by food restriction. Importantly, an increase in affinity of alpha-MSH reactive autoAbs was associated with changes of their functional roles from stimulation to inhibition of alpha-MSH-mediated behavioural responses, suggesting that these autoAbs can be a carrier or a neutralizing molecule of alpha-MSH peptide, respectively. Using a model of passive transfer into the brain, we show that alpha-MSH autoAbs affinity purified from blood of rats exposed to repeated mild stress, but not from control rats, are able to increase acutely food intake, suppress anxiety and modify gene expression of hypothalamic neuropeptides in naïve rats. These data provide the first evidence that autoAbs reactive with alpha-MSH are involved in the physiological regulation of feeding and mood, supporting a further role of the immune system in the control of motivated behavior and adaptation to stress.


Subject(s)
Anxiety/immunology , Autoantibodies/biosynthesis , Eating/immunology , Stress, Psychological/immunology , alpha-MSH/immunology , Animals , Antibody Affinity , Appetite , Autoantibodies/physiology , Female , Hypothalamus/immunology , Hypothalamus/metabolism , Immunization, Passive , Maze Learning , Neuropeptide Y/metabolism , RNA, Messenger/metabolism , Rats , Rats, Wistar , Stress, Psychological/psychology , alpha-MSH/blood
12.
Neuropsychopharmacology ; 34(2): 424-35, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18536705

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP) and the proopiomelanocortin (POMC)-derived peptide, alpha-melanocyte-stimulating hormone (alpha-MSH), exert anorexigenic activities. While alpha-MSH is known to inhibit food intake and stimulate catabolism via activation of the central melanocortin-receptor MC4-R, little is known regarding the mechanism by which PACAP inhibits food consumption. We have recently found that, in the arcuate nucleus of the hypothalamus, a high proportion of POMC neurons express PACAP receptors. This observation led us to investigate whether PACAP may inhibit food intake through a POMC-dependent mechanism. In mice deprived of food for 18 h, intracerebroventricular administration of PACAP significantly reduced food intake after 30 min, and this effect was reversed by the PACAP antagonist PACAP6-38. In contrast, vasoactive intestinal polypeptide did not affect feeding behavior. Pretreatment with the MC3-R/MC4-R antagonist SHU9119 significantly reduced the effect of PACAP on food consumption. Central administration of PACAP induced c-Fos mRNA expression and increased the proportion of POMC neuron-expressing c-Fos mRNA in the arcuate nucleus. Furthermore, PACAP provoked an increase in POMC and MC4-R mRNA expression in the hypothalamus, while MC3-R mRNA level was not affected. POMC mRNA level in the arcuate nucleus of PACAP-specific receptor (PAC1-R) knock-out mice was reduced as compared with wild-type animals. Finally, i.c.v. injection of PACAP provoked a significant increase in plasma glucose level. Altogether, these results indicate that PACAP, acting through PAC1-R, may inhibit food intake via a melanocortin-dependent pathway. These data also suggest a central action of PACAP in the control of glucose metabolism.


Subject(s)
Arcuate Nucleus of Hypothalamus/metabolism , Eating/drug effects , Hypothalamus/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology , Pro-Opiomelanocortin/metabolism , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Blood Glucose/analysis , Corticosterone/blood , Dose-Response Relationship, Drug , Eating/physiology , Hypothalamus/drug effects , Male , Melanocyte-Stimulating Hormones/pharmacology , Mice , Mice, Knockout , Neurons/drug effects , Neurons/metabolism , Neuropeptide Y/metabolism , Peptide Fragments/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitors , Pro-Opiomelanocortin/genetics , RNA, Messenger/metabolism , Receptor, Melanocortin, Type 3/antagonists & inhibitors , Receptor, Melanocortin, Type 3/metabolism , Receptor, Melanocortin, Type 4/antagonists & inhibitors , Receptor, Melanocortin, Type 4/metabolism , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Vasoactive Intestinal Peptide/pharmacology
13.
Eur J Pharmacol ; 569(3): 197-203, 2007 Aug 27.
Article in English | MEDLINE | ID: mdl-17574234

ABSTRACT

This study investigated, in mice, the antidepressant like effect of hyperfoliatin, a prenylated phloroglucinol derivative isolated from the aerial parts of Hypericum perfoliatum, as well as its action on monoaminergic systems. In the forced-swimming test, hyperfoliatin dose-dependently reduced immobility time. Immobility was interpreted as an expression of "behavioural despair", which could be a component of depression syndrome. The effect of hyperfoliatin did not result from the stimulation of animal motor activity. Hyperfoliatin inhibited, in a concentration-dependent manner, the [(3)H]-dopamine, [(3)H]-serotonin and [(3)H]-noradrenaline synaptosomal uptakes, but did not prevent the binding of specific ligands to the monoamine transporters. These data suggest that the antidepressant-like effect of hyperfoliatin on the forced-swimming test is probably associated to monoamine uptake inhibition, due to a mechanism of action different from that of known antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Depression/drug therapy , Hypericum/chemistry , Triterpenes/pharmacology , Animals , Antidepressive Agents/administration & dosage , Behavior, Animal/drug effects , Disease Models, Animal , Dopamine/metabolism , Dose-Response Relationship, Drug , Male , Mice , Motor Activity/drug effects , Neurotransmitter Uptake Inhibitors/administration & dosage , Neurotransmitter Uptake Inhibitors/pharmacology , Norepinephrine/metabolism , Phloroglucinol/analogs & derivatives , Phytotherapy , Plant Components, Aerial , Plant Extracts , Serotonin/metabolism , Swimming , Triterpenes/administration & dosage
14.
Neuropsychopharmacology ; 32(7): 1641-8, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17151595

ABSTRACT

Peptides of the endozepine family, including diazepam-binding inhibitor, the triakontatetraneuropeptide, and the octadecaneuropeptide (ODN), act through three types of receptors, that is, central-type benzodiazepine receptors (CBR), peripheral-type (mitochondrial) benzodiazepine receptors (PBR) and a metabotropic receptor positively coupled to phospholipase C via a pertussis toxin-sensitive G protein. We have previously reported that ODN exerts a potent anorexigenic effect in rat and we have found that the action of ODN is not affected by the mixed CBR/PBR agonist diazepam. In the present report, we have tested the possible involvement of the metabotropic receptor in the anorexigenic activity of ODN. Intracerebroventricular administration of the C-terminal octapeptide (OP) and its head-to-tail cyclic analog cyclo(1-8)OP (cOP) at a dose of 100 ng mimicked the inhibitory effect of ODN on food intake in food-deprived mice. The specific CBR antagonist flumazenil and the PBR antagonist PK11195 did not prevent the effect of ODN, OP, and cOP on food consumption. In contrast, the selective metabotropic endozepine receptor antagonist cyclo(1-8)[DLeu(5)]OP (100-1000 ng; cDLOP) suppressed the anorexigenic effect of ODN, OP, and cOP. At the highest concentration tested (1000 ng), cDLOP provoked by itself a significant increase in food intake. Taken together, the present results indicate that the anorexigenic effect of ODN and OP is mediated through activation of the metabotropic receptor recently characterized in astrocytes. The data also suggest that endogenous ODN, acting via this receptor, exerts an inhibitory tone on feeding behavior.


Subject(s)
Anorexia/metabolism , Appetite Regulation/physiology , Appetite/physiology , Diazepam Binding Inhibitor/metabolism , Hypothalamus/metabolism , Neuropeptides/metabolism , Peptide Fragments/metabolism , Receptors, G-Protein-Coupled/metabolism , Receptors, Neuropeptide/metabolism , Animals , Anorexia/chemically induced , Anorexia/physiopathology , Appetite/drug effects , Appetite Regulation/drug effects , Diazepam Binding Inhibitor/agonists , Diazepam Binding Inhibitor/chemistry , Dose-Response Relationship, Drug , Flumazenil/pharmacology , Food Deprivation/physiology , GABA Modulators/pharmacology , GABA-A Receptor Antagonists , Isoquinolines/pharmacology , Male , Mice , Motor Activity/drug effects , Motor Activity/physiology , Neuropeptides/agonists , Neuropeptides/chemistry , Peptide Fragments/agonists , Peptide Fragments/chemistry , Peptides/chemistry , Peptides/pharmacology , Receptors, G-Protein-Coupled/drug effects , Receptors, GABA-A/metabolism , Receptors, Neuropeptide/drug effects
15.
Fundam Clin Pharmacol ; 20(6): 507-14, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17109644

ABSTRACT

In this work, previously published and unpublished results on biological activity of Hypericum caprifoliatum, a native species to South Brazil, are presented. Lipophilic extracts obtained from this species showed an antidepressant-like activity in mice and rat forced swimming test. Results from in vivo experiments suggest an effect on the dopaminergic transmission. Besides that, in vitro experiments demonstrated that the extract and its main component (a phloroglucinol derivative) inhibit monoamine uptake in a concentration-dependent manner, more potently to dopamine, but this effect is not related to direct binding at the uptake sites. It was also observed that a 3-day treatment with lipophilic extract prevents stress-induced corticosterone rise in mice frontal cortex but not in plasma. The lipophilic and methanolic H. caprifoliatum extracts also demonstrated antinociceptive effect, which seems to be indirectly mediated by the opioid system. These results indicate that H. caprifoliatum presents a promising antidepressant-like effect in rodents which seems to be related to a mechanism different from that of other classes of antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Hypericum/chemistry , Plant Extracts/pharmacology , Animals , Antidepressive Agents/adverse effects , Antidepressive Agents/chemistry , Antidepressive Agents/therapeutic use , Anxiety/drug therapy , Brazil , Depression/drug therapy , Hypericum/adverse effects , Pain/drug therapy , Plant Extracts/adverse effects , Plant Extracts/therapeutic use , Rodentia , Seizures/drug therapy
16.
Peptides ; 27(5): 1110-20, 2006 May.
Article in English | MEDLINE | ID: mdl-16517014

ABSTRACT

A number of RFamide peptides have been characterized in invertebrate species and these peptides have been found to exert a broad spectrum of biological activities. In contrast, in vertebrates, our knowledge on RFamide peptides is far more limited and only a few members of the RFamide peptide family have been identified in various vertebrate classes during the last years. The present review focuses on two novel RFamide peptides, Rana RFamide (R-RFa) and 26RFa, that have been recently isolated from the amphibian brain. R-RFa shares the C-terminal LPLRFamide motif with other RFamide peptides previously identified in mammals, birds and fish. The distribution of R-RFa in the frog brain exhibits strong similarities with those of other LPLRFamide peptides, notably in the periventricular region of the hypothalamus. There is also evidence that the physiological functions of R-RFa and other LPLRFamide peptides have been conserved from fish to mammals; in particular, all these peptides appear to be involved in the control of pituitary hormone secretion. 26RFa does not exhibit any significant structural identity with other RFamide peptides and this peptide is the only member of the family that possesses an FRFamide motif at its C-terminus. The strong conservation of the primary structure of 26RFa from amphibians to mammals suggests that this RFamide peptide is involved in important biological functions in vertebrates. As for several other RFamide peptides, 26RFa-containing neurons are present in the hypothalamus, notably in two nuclei involved in the control of feeding behavior. Indeed, 26RFa is a potent stimulator of appetite in mammals. Concurrently, recent data suggest that 26RFa exerts various neuroendocrine regulatory activities at the pituitary and adrenal level.


Subject(s)
Hypothalamus/chemistry , Neuropeptides/chemistry , Neuropeptides/physiology , Animals , Central Nervous System/chemistry , Humans , Oligopeptides/analysis , Ranidae , Receptors, Neuropeptide/analysis
17.
Neuropharmacology ; 49(7): 1042-52, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16040063

ABSTRACT

A crude (ECH) and a purified cyclohexane extract (HCP) of Hypericum caprifoliatum and their main phloroglucinol derivative (HC1) were evaluated regarding their action on monoaminergic systems, more precisely on dopamine. In rats and mice forced swimming test, ECH and HCP dose-dependently reduced the immobility time. The effect of the highest dose was prevented by a prior administration of either sulpiride or SCH 23390 (D(2) and D(1) dopamine receptor antagonist, respectively). HCP (360 mg/kg) decreased the locomotor activity of mice. ECH (90 mg/kg) caused hypothermia and potentiated apomorphine-induced (16 mg/kg) hypothermia in mice. HCP and HC1 inhibited, in a concentration-dependent and monophasic manner, the [(3)H]-DA, [(3)H]-NA and [(3)H]-5HT synaptosomal uptakes, but did not prevent the binding of specific ligands to the monoamine transporters. Moreover, when tested at the concentrations corresponding to its IC(50) on [(3)H]-DA uptake, HC1 did not induce a significant [(3)H]-DA release, while at a higher concentration (200 ng/ml) it enhanced significantly (by 12%) the synaptosomal DA release. These data suggest that the antidepressant-like effect of H. caprifoliatum on the forced swimming test is due to an increase in monoaminergic transmission, resulting from monoamine uptake inhibition, more potently of dopamine, which may be related to their phloroglucinol contents.


Subject(s)
Antidepressive Agents/pharmacology , Depression/drug therapy , Hypericum/chemistry , Neurotransmitter Uptake Inhibitors/pharmacology , Animals , Apomorphine/pharmacology , Binding, Competitive/drug effects , Depression/etiology , Depression/psychology , Dopamine/physiology , Dopamine Agonists/pharmacology , Dose-Response Relationship, Drug , Hypothermia/chemically induced , Hypothermia/prevention & control , In Vitro Techniques , Male , Mice , Motor Activity/drug effects , Norepinephrine/physiology , Plant Extracts/pharmacology , Rats , Rats, Wistar , Serotonin/physiology , Swimming/psychology , Synaptosomes/drug effects , Synaptosomes/metabolism
18.
Proc Natl Acad Sci U S A ; 100(25): 15247-52, 2003 Dec 09.
Article in English | MEDLINE | ID: mdl-14657341

ABSTRACT

A neuropeptide was isolated from a frog brain extract by HPLC purification and characterized by mass spectrometry. This 26-aa neuropeptide, which belongs to the RFamide peptide family, was designated 26RFa, and its primary structure was established as VGTALGSLAEELNGYNRKKGGFSFRF-NH2. Research in databases revealed the presence of sequences homologous to frog 26RFa in the human genome and in rat ESTs. On the basis of this sequence information, the cDNAs encoding the human and rat 26RFa precursors were cloned. The two preproteins show a similar organization, with the 26RFa sequence located in the C-terminal region of the precursor. Human preprotein (prepro)-26RFa encodes an additional putative RFamide peptide that is not found in the rat precursor. The primary structures of human, rat, and frog 26RFa exhibit approximately 80% identity, and the C-terminal octapeptide has been fully conserved from amphibians to mammals. In situ hybridization histochemistry revealed that, in the rat brain, the 26RFa gene is exclusively expressed in the ventromedial hypothalamic nucleus and in the lateral hypothalamic area. 26RFa induced a dose-dependent stimulation in cAMP production by rat pituitary cells in vitro and markedly increased food intake in mice. The conservation of the primary structure of 26RFa during vertebrate evolution, the discrete localization of the mRNA encoding its precursor in hypothalamic nuclei involved in the control of feeding behavior, and the observation that 26RFa possesses orexigenic properties indicate that this neuropeptide may play important biological functions.


Subject(s)
Nerve Tissue Proteins/chemistry , Neuropeptides/chemistry , Peptides/chemistry , Amino Acid Sequence , Animals , Cell Nucleus/metabolism , Chromatography, High Pressure Liquid , Cloning, Molecular , Cyclic AMP/metabolism , DNA, Complementary/metabolism , Databases as Topic , Dose-Response Relationship, Drug , Expressed Sequence Tags , Genome, Human , Humans , Hypothalamus/metabolism , In Situ Hybridization , Male , Mass Spectrometry , Mice , Molecular Sequence Data , Nerve Tissue Proteins/biosynthesis , Peptide Biosynthesis , RNA, Messenger/metabolism , Ranidae , Rats , Rats, Wistar , Sequence Homology, Amino Acid , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL